DK1429807T3 - Kombination af et NSAID og en PDE4-inhibitor - Google Patents

Kombination af et NSAID og en PDE4-inhibitor

Info

Publication number
DK1429807T3
DK1429807T3 DK02772313T DK02772313T DK1429807T3 DK 1429807 T3 DK1429807 T3 DK 1429807T3 DK 02772313 T DK02772313 T DK 02772313T DK 02772313 T DK02772313 T DK 02772313T DK 1429807 T3 DK1429807 T3 DK 1429807T3
Authority
DK
Denmark
Prior art keywords
combination
nsaid
pde4 inhibitor
derivative
inhibitor
Prior art date
Application number
DK02772313T
Other languages
Danish (da)
English (en)
Inventor
Thomas Klein
Hans-Peter Kley
Armin Hatzelmann
Manfrid Eltze
Original Assignee
Altana Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altana Pharma Ag filed Critical Altana Pharma Ag
Application granted granted Critical
Publication of DK1429807T3 publication Critical patent/DK1429807T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK02772313T 2001-09-19 2002-09-17 Kombination af et NSAID og en PDE4-inhibitor DK1429807T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01000473 2001-09-19
PCT/EP2002/010424 WO2003024489A2 (fr) 2001-09-19 2002-09-17 Combinaison d'un ains et d'un inhibiteur de pde4

Publications (1)

Publication Number Publication Date
DK1429807T3 true DK1429807T3 (da) 2007-06-18

Family

ID=8176065

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02772313T DK1429807T3 (da) 2001-09-19 2002-09-17 Kombination af et NSAID og en PDE4-inhibitor

Country Status (25)

Country Link
US (2) US20040242597A1 (fr)
EP (1) EP1429807B1 (fr)
JP (1) JP4588998B2 (fr)
KR (1) KR100949528B1 (fr)
CN (1) CN100496607C (fr)
AT (1) ATE355080T1 (fr)
AU (1) AU2002337105B2 (fr)
BR (1) BR0212606A (fr)
CA (1) CA2459757C (fr)
CY (1) CY1108011T1 (fr)
DE (1) DE60218497T2 (fr)
DK (1) DK1429807T3 (fr)
EA (1) EA008108B1 (fr)
ES (1) ES2282469T3 (fr)
HK (1) HK1066730A1 (fr)
HU (1) HU229442B1 (fr)
IL (2) IL160271A0 (fr)
MX (1) MXPA04002562A (fr)
NO (1) NO331756B1 (fr)
NZ (1) NZ532278A (fr)
PL (1) PL210463B1 (fr)
PT (1) PT1429807E (fr)
SI (1) SI1429807T1 (fr)
WO (1) WO2003024489A2 (fr)
ZA (1) ZA200402654B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004110424A1 (fr) * 2003-05-28 2004-12-23 Glaxo Group Limited Procede et formulation pharmaceutique pour reduire chez un mammifere l'acceleration du transfert colique induite par le stress
WO2005016334A1 (fr) * 2003-08-07 2005-02-24 B.M.R.A. Corporation B.V. Compositions et procedes bases sur une association d'un antagoniste du recepteur de thromboxane a2 et d'un inhibiteur de cyclooxygenase-1
EP1691797A2 (fr) * 2003-10-21 2006-08-23 Pharmacia Corporation Un inhibiteur de cyclooxygenase-2 combine a un inhibiteur de phosphodiesterase 4 et methode
EP1683521A1 (fr) * 2005-01-21 2006-07-26 Centre National De La Recherche Scientifique (Cnrs) Inhibiteurs de la peptide deformylase, leur utilisations et compositions pharmacéutiques qui les contiennent
EP1688413A1 (fr) * 2005-02-03 2006-08-09 Hikma Pharmaceuticals Co. Ltd. Dérivés de benzoxazole pour la prophylaxie et le traitement des inflammations intestinales
CA2600822A1 (fr) * 2005-03-14 2006-09-21 Nycomed Gmbh Procede de prevention des maladies cardiovasculaires
EP1898894A1 (fr) * 2005-06-17 2008-03-19 Boehringer Ingelheim International GmbH Inhibiteurs mrp iv pour le traitement de maladies respiratoires
DK2012763T3 (da) * 2006-04-28 2011-05-02 Gruenenthal Gmbh Farmaceutisk kombination omfattende 3-(3-dimethylamono-1-ethyl-2-methyl-propyl) phenol og et NSAID
FR2909876A1 (fr) * 2006-12-19 2008-06-20 Galderma Res & Dev S N C Snc Utilisation du nepafenac ou ses derives pour le traitement de desordres dermatologiques
JP5406215B2 (ja) 2008-01-25 2014-02-05 ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー ＴＮＦ−α合成の調節因子及びＰＤＥ４阻害剤としての三環系化合物
US8298536B2 (en) * 2008-03-04 2012-10-30 Pfizer Limited Methods of treating inflammatory pain
CA2753604A1 (fr) * 2009-02-27 2010-09-02 Boehringer Ingelheim International Gmbh Associations de medicaments contenant des inhibiteurs de pde4 et des ains
EP2400961B1 (fr) 2009-02-27 2017-11-22 Boehringer Ingelheim International GmbH Combinaisons de médicaments contenant des inhibiteurs pde4 et nsaid
CN105121439A (zh) 2013-02-19 2015-12-02 辉瑞公司 作为pde4亚型抑制剂用于治疗cns和其他病症的氮杂苯并咪唑化合物
EP3172210B1 (fr) 2014-07-24 2020-01-15 Pfizer Inc Composés de pyrazolopyrimidine
KR102061952B1 (ko) 2014-08-06 2020-01-02 화이자 인코포레이티드 이미다조피리다진 화합물
WO2019147824A1 (fr) 2018-01-26 2019-08-01 Progenity, Inc. Traitement d'une maladie du tractus gastro-intestinal avec un inhibiteur de pde4
WO2020106754A1 (fr) 2018-11-19 2020-05-28 Progenity, Inc. Méthodes et dispositifs pour traiter une maladie à l'aide d'agents biothérapeutiques
EP4069213A1 (fr) * 2019-12-03 2022-10-12 The USA, as represented by The Secretary, Department of Health and Human Services Inhibition de la cyclooxygénase 2 permettant le traitement de l'asthme à saa élevé
WO2021119482A1 (fr) 2019-12-13 2021-06-17 Progenity, Inc. Dispositif ingérable pour administrer un agent thérapeutique dans le tractus gastro-intestinal
US20230090417A1 (en) * 2021-09-22 2023-03-23 Iolyx Therapeutics, Inc. Methods of treating ocular inflammatory diseases

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1229075B (it) * 1985-04-05 1991-07-17 Fidia Farmaceutici Medicamenti per uso topico, ottenuti tramite l'impiego dell'acido ialuronico
GB2228736A (en) 1989-02-10 1990-09-05 Sterivet Lab Ltd Cosmetic formulation
ES2137113B1 (es) * 1997-07-29 2000-09-16 Almirall Prodesfarma Sa Nuevos derivados de triazolo-piridazinas heterociclicos.
ID23921A (id) 1997-11-04 2000-05-25 Pfizer Prod Inc Penggantian indazola bioisostere katekol pada senyawa-senyawa aktif untuk terapi
NZ515711A (en) 1999-06-24 2004-01-30 Pharmacia Corp Combination of tumors necrocis factor (TNF) antagonists and COX-2 inhibitors for the treatment of inflammation
EP2193808A1 (fr) * 1999-08-21 2010-06-09 Nycomed GmbH Combinaision synergique
US6174878B1 (en) * 1999-08-31 2001-01-16 Alcon Laboratories, Inc. Topical use of kappa opioid agonists to treat otic pain
ECSP003747A (es) * 1999-11-02 2002-05-23 Smithkline Beecham Corp Metodo y composiciones para el tratamiento de las enfermedades pulmonares
US6410563B1 (en) * 1999-12-22 2002-06-25 Merck Frosst Canada & Co. Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
US6372777B1 (en) * 1999-12-23 2002-04-16 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
KR20020072299A (ko) * 2000-01-31 2002-09-14 화이자 프로덕츠 인코포레이티드 Ｐｄｅ4 이소자임의 선택적 억제제로서 유용한니코틴아미드 벤조접합된-헤테로사이클릴 유도체
JP2003522142A (ja) * 2000-02-08 2003-07-22 スミスクライン・ビーチャム・コーポレイション 炎症性疾患の治療法および治療用組成物
PL364910A1 (en) * 2001-01-31 2004-12-27 Pfizer Products Inc. Ether derivatives useful as inhibitors of pde4 isozymes
EE05386B1 (et) * 2001-02-15 2011-02-15 ALTANA�Pharma�AG Ftalasinoon-piperidinoderivaadid,ÁnendeÁkasutamineÁjaÁravim

Also Published As

Publication number Publication date
US20080255209A1 (en) 2008-10-16
EP1429807B1 (fr) 2007-02-28
EP1429807A2 (fr) 2004-06-23
JP2005504077A (ja) 2005-02-10
CA2459757A1 (fr) 2003-03-27
KR100949528B1 (ko) 2010-03-25
HK1066730A1 (en) 2005-04-01
CA2459757C (fr) 2011-08-30
HU229442B1 (hu) 2013-12-30
DE60218497T2 (de) 2007-11-08
PT1429807E (pt) 2007-05-31
IL160271A (en) 2008-03-20
MXPA04002562A (es) 2004-05-31
EA008108B1 (ru) 2007-04-27
ZA200402654B (en) 2005-04-26
IL160271A0 (en) 2004-07-25
US8242146B2 (en) 2012-08-14
HUP0401582A3 (en) 2008-04-28
US20040242597A1 (en) 2004-12-02
AU2002337105B2 (en) 2008-03-20
ATE355080T1 (de) 2006-03-15
NZ532278A (en) 2006-02-24
CY1108011T1 (el) 2013-09-04
WO2003024489A3 (fr) 2003-09-18
PL369472A1 (en) 2005-04-18
KR20040053129A (ko) 2004-06-23
HUP0401582A2 (hu) 2004-11-29
CN1625411A (zh) 2005-06-08
NO331756B1 (no) 2012-03-19
BR0212606A (pt) 2004-08-17
JP4588998B2 (ja) 2010-12-01
DE60218497D1 (de) 2007-04-12
EA200400410A1 (ru) 2004-12-30
CN100496607C (zh) 2009-06-10
WO2003024489A2 (fr) 2003-03-27
SI1429807T1 (sl) 2007-08-31
NO20041596L (no) 2004-06-18
ES2282469T3 (es) 2007-10-16
PL210463B1 (pl) 2012-01-31

Similar Documents

Publication Publication Date Title
DK1429807T3 (da) Kombination af et NSAID og en PDE4-inhibitor
CY1109529T1 (el) 2-(αμινο-υποκατεστημενες)-4-αρυλο πυραμιδινες και σχετικες ενωσεις που χρησιμευουν στην αγωγη φλεγμονωδων νοσηματων
IS7099A (is) Efnasambönd til að meðhöndla bólgutruflanir
CY1105586T1 (el) Ιμιδαζοκουινολινες υποκατεστημενες με θειοαιθερα
CY1106357T1 (el) Παραγωγα αδαμαντανιου για τη θepαπεια φλεγμονωδων, ανοσολογικων και καρδιαγγειακων ασθενειων
BRPI0411825A (pt) inibidores de p38 quinase a base de heterociclo de 5 elementos
IS2457B (is) Samsetningar af lyfjum (t.d. klórprómasíni og pentamídíni) fyrir meðhöndlun á æxlistruflunum
DK1423381T3 (da) 17beta-hydroxysteroid-dehydrogenase type 3-inhibitorer til behandling af androgenafhængige sygdomme
NO20035474D0 (no) Prodrugs av GABA-analoger, sammensetninger og anvendelse derav
DK2287156T3 (da) 2,4-Di(phenylamino)-pyrimidiner egnede i behandling af neoplastiske sygdomme, inflammatoriske lidelser og lidelser i immunsystemet
DK2014304T3 (da) Kolonrensende sammensætninger
CY1113651T1 (el) Αντιφλεγμονωδη σκευασματα
DK2090575T3 (da) Fremgangsmåder og mellemprodukter til fremstillingen af N4 phenylquinazolin-4-aminderivater
DK1412357T3 (da) Beta-aminotetrahydroimidazo-(1,2-a)-pyraziner og tetrahydrotriazolo-(4,3-a)-pyraziner som dipeptidylpeptidaseinhibitorer til behandling eller forebyggelse af diabetes
DK1360202T3 (da) Langvarigt glucagon-lignende peptid 2 (GLP-2) til behandling af gastrointestinale sygdomme og lidelser
DK1644021T3 (da) Fremgangsmåder og sammensætninger til behandlingen af gastrointestinale sygdomme
IS7202A (is) Samsetningar til meðhöndlunar á ónæmisbólgusjúkdómum
DK1871380T3 (da) Kombineret anvendelse af prostaglandinforbindelse og protonpumpeinhibitor til behandlingen af gastrointestinale lidelser
DK1313740T3 (da) Prodrugs af imidazopyridinderivater
UA85711C2 (ru) Замещенные енаминоны, их производные и их применение
DK1344526T3 (da) Midler til forebyggelse/behandling af inflammatoriske luftvejslidelser
SE0102808D0 (sv) New compounds
NO20052264D0 (no) Pregahalinderivater for behandling av fibromyalgi og andre forstyrrelser
EE05263B1 (et) IL-18 inhibiitorite kasutamine keskn„rvissteemi kahjustuste raviks v?i ennetamiseks
MY141010A (en) Use of ppar agonists for the treatment of congestive heart failure